0000000000308710

AUTHOR

M. Guillemin

showing 3 related works from this author

Implementation of routine sequential PET/MR of the rat heart in an in-line preclinical scanner

2016

International audience

[SDV.IB] Life Sciences [q-bio]/Bioengineering[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV.IB]Life Sciences [q-bio]/Bioengineering[ SDV.IB ] Life Sciences [q-bio]/Bioengineering[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingComputingMilieux_MISCELLANEOUS[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
researchProduct

Validation of SiPM-based PET imaging for left ventricular volumes measurements in preclinical imaging: comparison with simultaneously-acquired cardia…

2018

International audience

[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineComputingMilieux_MISCELLANEOUS[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
researchProduct

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

2017

International audience; Improved bifunctional chelating agents (BFC) are required for copper-64 radiolabelling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific imaging agents. Four different bifunctional chelating agents (BFC) were evaluated for Fab (Fragment antigen binding) conjugation and radiolabelling with copper-64. Two DOTA- (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and two NOTA- (1,4,7-triazacyclononane-1,4,7-triacetic acid) derivatives bearing a p-benzyl-isothiocyanate group were conjugated to Fab-trastuzumab - which targets the HER2/neu receptor - and the average number of chelators attached ranged from 2.4 to 4.3 macrocycles …

BiodistributionImmunoconjugatesmedicine.drug_class[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibody030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/CancerInorganic ChemistryHeterocyclic Compounds 1-RingImmunoglobulin Fab FragmentsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineAnimalsHumansDOTA[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyTissue DistributionChelationBifunctionalChelating AgentsRadiochemistryMammary Neoplasms ExperimentalTrastuzumabIn vitroImmunoconjugateCopper RadioisotopesBiochemistrychemistryPositron-Emission Tomography030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/ImmunologyCopper-64
researchProduct